Literature DB >> 7238645

Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension.

F H Claas, R J Smeenk, R Schmidt, G J van Steenbrugge, J G Eernisse.   

Abstract

Repeated platelet transfusion to thrombocytopenic patients frequently induce anti HLA antibodies, which are responsible for transfusion refractoriness. As the transfused platelet suspensions usually contain 15-30% of the leukocytes originally present in the blood, it is not known whether these antibodies are raised by the platelets or by the contaminating leukocytes in the platelet suspensions. In the mouse, pure platelet suspensions are not able to induce a primary antibody response, as measured by the NIH test and the indirect immunofluorescence test on platelets and leukocytes, despite repeated injections. However, when the platelet suspensions are contaminated with leukocytes (10(3) or more/injection) an antibody response is induced. This response is higher than the response indiced by an equal amount of leukocytes alone. As in man the use of leukocyte poor platelets postpones the development of refractoriness to random platelets it is concluded that transfusions with leukocyte free platelets will probably prevent immunization against the HLA antigens.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7238645

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  17 in total

Review 1.  Leucoreduction of blood components: an effective way to increase blood safety?

Authors:  Maria Bianchi; Stefania Vaglio; Simonetta Pupella; Giuseppe Marano; Giuseppina Facco; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-12-16       Impact factor: 3.443

Review 2.  Supportive care in patients with acute leukaemia: historical perspectives.

Authors:  Giovanna Cannas; Xavier Thomas
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

3.  Leucodepletion and Blood Products.

Authors:  Harsh Kumar; P K Gupta; D K Mishra; R S Sarkar; M Jaiprakash
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Time Dependent Release of Interleukin-8 and Tumor Necrosis Factor-α in Platelet Concentrate.

Authors:  Rinku V Shukla; Tanvi G Patel; Snehalata C Gupte
Journal:  Indian J Hematol Blood Transfus       Date:  2014-07-30       Impact factor: 0.900

5.  The impact of the HLA system in clinical hematology.

Authors:  J J van Rood
Journal:  Blut       Date:  1989-09

Review 6.  The use of blood components in patients with malignancy.

Authors:  S Murphy
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

7.  Serological findings and efficiency of DNA profiling in transfused patients and their significance for identity and paternity tests.

Authors:  W Huckenbeck; S Rand
Journal:  Int J Legal Med       Date:  1994       Impact factor: 2.686

Review 8.  Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens.

Authors:  Seema R Patel; James C Zimring
Journal:  Transfus Med Rev       Date:  2013-10-03

9.  Leukodepleted blood components do not remove the potential for long-term transfusion-associated microchimerism in Australian major trauma patients.

Authors:  Rena Hirani; Zsolt J Balogh; Natalie J Lott; Jeremy M Hsu; David O Irving
Journal:  Chimerism       Date:  2015-08-07

10.  Activation of lymphocytes after platelet allotransfusion possessing only class I MHC product.

Authors:  E Pócsik; R Mihalik; E Gyódi; M Réti; K Pálóczi; G G Petrányi; M Benczúr
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.